search
Back to results

Lipid Lowering Effect of Plant Stanol Ester in a Spoonable Non-dairy Product

Primary Purpose

Hypercholesterolemia

Status
Completed
Phase
Not Applicable
Locations
Finland
Study Type
Interventional
Intervention
Product that contains plant stanol ester
Placebo product
Sponsored by
Raisio Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypercholesterolemia

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Signed written informed consent
  • Mildly or moderately elevated plasma cholesterol levels (plasma total cholesterol 5.5-8.0 mmol/l)
  • Plasma triglyceride levels ≤ 4.0 mmol/l
  • Age 18-65 years

Exclusion Criteria:

  • Intolerance to oats or other ingredients of the test products
  • Severe obesity (BMI ≥ 32 kg/m2)
  • Consumption of lipid/cholesterol lowering medication (e.g. ezetimibe, PCSK9 inhibitors, resins, fibrates) 1 month prior to the screening visit and throughout the study. Statin treatment is allowed at stable dose.
  • Consumption of plant stanol or plant sterol containing food products or supplements such as Benecol, Becel pro.active, Keiju Alentaja or other foods or supplements such as beta-glucan enriched foods, red rice, berberine or any combination of these used for cholesterol lowering purpose 1 month prior the study entry (baseline blood sample)
  • History of malignant diseases like cancer within five years prior to recruitment
  • History of unstable coronary artery disease (myocardial infarction, coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA) within the previous 6 months
  • Diagnosed type 1 or type 2 diabetes requiring medical treatment
  • Celiac disease
  • Medically prescribed diet/treatment for slimming or a special diet like very low calorie diet or use of prescribed an obesity drug (e.g. Orlistat, Victoza)
  • Alcohol abuse (> 4 portion/per day) or recreational drug abuse
  • Pregnancy or planned pregnancy or lactating
  • Clinically significant abnormalities in screening labs
  • Participation in another clinical trial in the preceding 3 months

Sites / Locations

  • Nightingale Health plc

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Plant stanol ester comparator

Placebo comparator

Arm Description

Product that contains plant stanol ester

Placebo product

Outcomes

Primary Outcome Measures

Change in LDL cholesterol concentration (%)
Mean relative change in serum LDL cholesterol concentration during the intervention

Secondary Outcome Measures

LDL cholesterol concentration
Mean absolute change in serum LDL cholesterol concentration during the intervention between test and control group
total cholesterol concentration
Changes in serum total cholesterol concentration during the intervention
HDL cholesterol concentration
Changes in serum HDL cholesterol concentration during the intervention
non-HDL cholesterol concentration
Changes in serum non-HDL cholesterol concentration during the intervention
Total triglyceride concentration
Changes in serum triglycerides concentrations
NMR blood biomarkers
Changes in specific NMR blood biomarkers

Full Information

First Posted
September 10, 2021
Last Updated
December 2, 2021
Sponsor
Raisio Group
search

1. Study Identification

Unique Protocol Identification Number
NCT05064644
Brief Title
Lipid Lowering Effect of Plant Stanol Ester in a Spoonable Non-dairy Product
Official Title
Lipid Lowering Effect of Plant Stanol Ester in Oat-based, Fermented Spoonable Dairy Analogue -a 3-week Randomized, Double-blind, Placebo-controlled, Parallel-group Intervention Study
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Completed
Study Start Date
August 1, 2021 (Actual)
Primary Completion Date
October 30, 2021 (Actual)
Study Completion Date
November 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Raisio Group

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim is to determine the effect of investigational products on serum LDL cholesterol.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypercholesterolemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
55 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Plant stanol ester comparator
Arm Type
Active Comparator
Arm Description
Product that contains plant stanol ester
Arm Title
Placebo comparator
Arm Type
Placebo Comparator
Arm Description
Placebo product
Intervention Type
Other
Intervention Name(s)
Product that contains plant stanol ester
Intervention Description
Product with active ingredient
Intervention Type
Other
Intervention Name(s)
Placebo product
Intervention Description
Product without active ingredient
Primary Outcome Measure Information:
Title
Change in LDL cholesterol concentration (%)
Description
Mean relative change in serum LDL cholesterol concentration during the intervention
Time Frame
0 vs 3 weeks
Secondary Outcome Measure Information:
Title
LDL cholesterol concentration
Description
Mean absolute change in serum LDL cholesterol concentration during the intervention between test and control group
Time Frame
0 vs 3 weeks
Title
total cholesterol concentration
Description
Changes in serum total cholesterol concentration during the intervention
Time Frame
0 vs 3 weeks
Title
HDL cholesterol concentration
Description
Changes in serum HDL cholesterol concentration during the intervention
Time Frame
0 vs 3 weeks
Title
non-HDL cholesterol concentration
Description
Changes in serum non-HDL cholesterol concentration during the intervention
Time Frame
0 vs 3 weeks
Title
Total triglyceride concentration
Description
Changes in serum triglycerides concentrations
Time Frame
0 vs 3 weeks
Title
NMR blood biomarkers
Description
Changes in specific NMR blood biomarkers
Time Frame
0 vs 3 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Signed written informed consent Mildly or moderately elevated plasma cholesterol levels (plasma total cholesterol 5.5-8.0 mmol/l) Plasma triglyceride levels ≤ 4.0 mmol/l Age 18-65 years Exclusion Criteria: Intolerance to oats or other ingredients of the test products Severe obesity (BMI ≥ 32 kg/m2) Consumption of lipid/cholesterol lowering medication (e.g. ezetimibe, PCSK9 inhibitors, resins, fibrates) 1 month prior to the screening visit and throughout the study. Statin treatment is allowed at stable dose. Consumption of plant stanol or plant sterol containing food products or supplements such as Benecol, Becel pro.active, Keiju Alentaja or other foods or supplements such as beta-glucan enriched foods, red rice, berberine or any combination of these used for cholesterol lowering purpose 1 month prior the study entry (baseline blood sample) History of malignant diseases like cancer within five years prior to recruitment History of unstable coronary artery disease (myocardial infarction, coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA) within the previous 6 months Diagnosed type 1 or type 2 diabetes requiring medical treatment Celiac disease Medically prescribed diet/treatment for slimming or a special diet like very low calorie diet or use of prescribed an obesity drug (e.g. Orlistat, Victoza) Alcohol abuse (> 4 portion/per day) or recreational drug abuse Pregnancy or planned pregnancy or lactating Clinically significant abnormalities in screening labs Participation in another clinical trial in the preceding 3 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Helena Gylling, MD
Organizational Affiliation
Helsinki University Hospital, Helsinki, Finland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nightingale Health plc
City
Helsinki
ZIP/Postal Code
00330
Country
Finland

12. IPD Sharing Statement

Learn more about this trial

Lipid Lowering Effect of Plant Stanol Ester in a Spoonable Non-dairy Product

We'll reach out to this number within 24 hrs